青囊斑龙丸加减方治疗脾肾两虚型肿瘤相关性贫血的临床观察

发布时间：2018-03-08 21:02

  本文选题：肿瘤相关性贫血　切入点：脾肾两虚　出处：《广州中医药大学》2016年硕士论文　论文类型：学位论文

【摘要】：目的：观察青囊斑龙丸加减方治疗脾肾两虚型肿瘤相关性贫血的临床观察。方法：本研究收集的病例来自广州中医药大学第一附属医院肿瘤中心一区的肿瘤患者,将符合入组标准的病例随机分为治疗组与对照组,其中治疗组24例病例,对照组23例病例,治疗组予青囊斑龙丸加减方治疗,连续服用14天,其余支持治疗同空白对照组；空白对照组仅予支持治疗,不予任何治疗贫血的干预措施。分别于入组第0、14天进行访视,记录贫血疗效指标(血红蛋白水平)、中医证候积分、KPS评分和安全性指标(生化全套检查及不良反应的发生),最后统计数据利用SPSS 22.0统计软件进行分析(所有统计均采用双侧检验,当P值≤0.05时,则认为所检验差别有统计学意义),比较两组的贫血疗效、中医证候疗效和生活质量疗效。结果：治疗组血红蛋白水平平均较前上升4.75g/L,而对照组则下降3.39g几,经t检验有统计学意义(P0.05)；但贫血疗效评价方面,治疗组仅有16.67%评价为有效或显效,对照组为8.70%,经Ridit分析无统计学意义(P0.05),所以,治疗组的贫血疗效并不优于对照组。在中医证候疗效方面,治疗组评价为有效的有91.67%,对照组评价为有效的仅有8.70%,经Ridit分析有统计学意义(P=00.05),所以,治疗组的中医证候疗效要优于对照组。在生活质量疗效方面,治疗组疗后卡氏评分改善的有62.50%,对照组则为8.70%,经Ridit分析有统计学意义(P=00.05),所以,治疗组的生活质量疗效要优于对照组。最后,在不良事件方面,治疗组与对照组均未见肝功能恶化及肾功能恶化,但是治疗组的口干、咽痛、恶心等不良反应比对照组的发生率要稍高,经Ridit分析无统计学意义(P=0.8400.05),所以,治疗组与对照组的不良事件发生率并无显著差异。结论：运用青囊斑龙丸加减方治疗脾肾两虚型肿瘤相关性贫血的患者,在贫血的改善上无明显疗效,但是在中医证候及生活质量的治疗上,有明显的疗效,所以,青囊斑龙丸加减方对脾肾两虚型肿瘤相关性贫血患者有改善症状、提高生活质量的作用。
[Abstract]:Objective: to observe the clinical observation on the treatment of tumor-associated anemia with deficiency of spleen and kidney with the addition and subtraction of Qingcao Banlong Pill. Methods: the patients from the first affiliated Hospital of Guangzhou University of traditional Chinese Medicine in the first area of the tumor center were collected in this study. The patients who met the criteria were randomly divided into treatment group (n = 24) and control group (n = 23). The blank control group was treated with support therapy only, and no intervention was taken to treat anemia. The effective indexes of anemia (hemoglobin level, TCM syndromes score, KPS score and safety index) were recorded. The final statistical data were analyzed by SPSS 22.0 software (all statistics). All of them were tested on both sides. When P value 鈮，

本文编号：1585519